Skip to main content
Erschienen in: Digestive Diseases and Sciences 9/2020

10.01.2020 | Original Article

Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

verfasst von: Vanessa States, Stephen O’Brien, Jayesh P. Rai, Henry L. Roberts, Mason Paas, Kayla Feagins, Evangeline J. Pierce, Richard N. Baumgartner, Susan Galandiuk

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Pyoderma gangrenosum (PG) is an uncommon but severe extra-intestinal manifestation (EIM) of inflammatory bowel disease (IBD). The incidence and risk factors for PG are disputed.

Aims

To assess the incidence of PG and identify factors associated with PG in IBD patients.

Methods

A search of electronic databases (Ovid and PubMed) was conducted between 1966 and 2019. Studies that calculated the incidence of PG in IBD patient cohorts were included. Patient demographics, IBD subtype, and EIM presence were recorded. A review of our institutional database of 1057 IBD patients was conducted. A multivariate regression model and meta-analysis were conducted to identify risk factors for PG. A random effects model was used to combine the data of included studies.

Results

Fourteen studies were included in addition to 1057 IBD patients and 26 PG cases from the Louisville cohort. In total, there were 379 cases of PG in the cumulative cohort of 61,695 IBD patients. The PG incidence in individual studies ranged from 0.4 to 2.6%. In the institutional cohort, ocular EIMs and a permanent stoma were significant risk factors for PG. In the meta-analysis, PG was associated with female gender (RR = 1.328, 95% CI 1.161–1.520), Crohn’s disease (RR = 1.193, 95% CI 1.001–1.422), erythema nodosum (RR = 9.281, 95% CI 6.081–14.164), and ocular EIM (RR = 4.55, 95% CI 3.04–6.81). There was study heterogeneity when assessing IBD subtype, ocular, and joint EIMs.

Conclusions

There are conflicting data on the incidence and risk factors for PG. This meta-analysis confirms an association between PG and female gender, Crohn’s disease, erythema nodosum, and ocular EIM that have been described in smaller studies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5:1424–1429. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5:1424–1429.
2.
Zurück zum Zitat Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9:2300–2307.PubMedPubMedCentralCrossRef Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9:2300–2307.PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Roberts H, Rai SN, Pan J, et al. Extraintestinal manifestations of inflammatory bowel disease and the influence of smoking. Digestion. 2014;90:122–129.PubMedCrossRef Roberts H, Rai SN, Pan J, et al. Extraintestinal manifestations of inflammatory bowel disease and the influence of smoking. Digestion. 2014;90:122–129.PubMedCrossRef
4.
Zurück zum Zitat Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004;10:207–214.PubMedCrossRef Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004;10:207–214.PubMedCrossRef
5.
Zurück zum Zitat Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29–34.PubMedCrossRef Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29–34.PubMedCrossRef
6.
Zurück zum Zitat Christodoulou DK, Katsanos KH, Kitsanou M, Stergiopoulou C, Hatzis J, Tsianos EV. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2002;34:781–786. Christodoulou DK, Katsanos KH, Kitsanou M, Stergiopoulou C, Hatzis J, Tsianos EV. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2002;34:781–786.
7.
Zurück zum Zitat Garg A, Hundal J, Strunk A. Overall and subgroup prevalence of Crohn disease among patients with hidradenitis suppurativa: a population-based analysis in the United States. JAMA Dermatol. 2018;154:814–818.PubMedPubMedCentralCrossRef Garg A, Hundal J, Strunk A. Overall and subgroup prevalence of Crohn disease among patients with hidradenitis suppurativa: a population-based analysis in the United States. JAMA Dermatol. 2018;154:814–818.PubMedPubMedCentralCrossRef
9.
10.
Zurück zum Zitat Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am J Clin Dermatol. 2018;19:479–487.PubMedCrossRef Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am J Clin Dermatol. 2018;19:479–487.PubMedCrossRef
11.
Zurück zum Zitat Tuffaha SH, Sarhane KA, Mundinger GS, et al. Pyoderma gangrenosum after breast surgery: diagnostic pearls and treatment recommendations based on a systematic literature review. Ann Plast Surg. 2016;77:e39–e44.PubMedCrossRef Tuffaha SH, Sarhane KA, Mundinger GS, et al. Pyoderma gangrenosum after breast surgery: diagnostic pearls and treatment recommendations based on a systematic literature review. Ann Plast Surg. 2016;77:e39–e44.PubMedCrossRef
12.
Zurück zum Zitat Xia FD, Liu K, Lockwood S, et al. Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum—a retrospective analysis. J Am Acad Dermatol. 2018;78:e311. Xia FD, Liu K, Lockwood S, et al. Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum—a retrospective analysis. J Am Acad Dermatol. 2018;78:e311.
13.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.PubMedPubMedCentralCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Mahid SS, Hornung CA, Minor KS, Turina M, Galandiuk S. Systematic reviews and meta-analysis for the surgeon scientist. Br J Surg. 2006;93:1315–1324.PubMedCrossRef Mahid SS, Hornung CA, Minor KS, Turina M, Galandiuk S. Systematic reviews and meta-analysis for the surgeon scientist. Br J Surg. 2006;93:1315–1324.PubMedCrossRef
15.
Zurück zum Zitat Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–826.PubMedCrossRef Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–826.PubMedCrossRef
16.
Zurück zum Zitat U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Questionnaire. Accessed February 24, 2018; 2018. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Questionnaire. Accessed February 24, 2018; 2018.
17.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.PubMedCrossRef
18.
Zurück zum Zitat Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed). 2003;327:557–560.CrossRef Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed). 2003;327:557–560.CrossRef
19.
Zurück zum Zitat Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins; 2008. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins; 2008.
20.
Zurück zum Zitat Polcz M, Gu J, Florin T. Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services’ Adult Hospital 1998–2009. J Crohn’s Colitis. 2011;5:148–151.CrossRef Polcz M, Gu J, Florin T. Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services’ Adult Hospital 1998–2009. J Crohn’s Colitis. 2011;5:148–151.CrossRef
21.
Zurück zum Zitat Yuksel I, Basar O, Ataseven H, et al. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:546–550.PubMedCrossRef Yuksel I, Basar O, Ataseven H, et al. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:546–550.PubMedCrossRef
22.
Zurück zum Zitat Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine. 2008;87:281–293.PubMedCrossRef Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine. 2008;87:281–293.PubMedCrossRef
23.
Zurück zum Zitat Moravvej H, Razavi GM, Farshchian M, Malekzadeh R. Cutaneous manifestations in 404 Iranian patients with inflammatory bowel disease: a retrospective study. Indian J Dermatol Venereol Leprol. 2008;74:607–610.PubMedCrossRef Moravvej H, Razavi GM, Farshchian M, Malekzadeh R. Cutaneous manifestations in 404 Iranian patients with inflammatory bowel disease: a retrospective study. Indian J Dermatol Venereol Leprol. 2008;74:607–610.PubMedCrossRef
24.
Zurück zum Zitat Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–119.PubMedCrossRef Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–119.PubMedCrossRef
25.
Zurück zum Zitat Mebazaa A, Aounallah A, Naija N, et al. Dermatologic manifestations in inflammatory bowel disease in Tunisia. La Tunisie Med. 2012;90:252–257.PubMed Mebazaa A, Aounallah A, Naija N, et al. Dermatologic manifestations in inflammatory bowel disease in Tunisia. La Tunisie Med. 2012;90:252–257.PubMed
26.
Zurück zum Zitat Isene R, Bernklev T, Hoie O, et al. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50:300–305.PubMedCrossRef Isene R, Bernklev T, Hoie O, et al. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50:300–305.PubMedCrossRef
27.
Zurück zum Zitat Ampuero J, Rojas-Feria M, Castro-Fernandez M, Cano C, Romero-Gomez M. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J Gastroenterol Hepatol. 2014;29:291–295.PubMedCrossRef Ampuero J, Rojas-Feria M, Castro-Fernandez M, Cano C, Romero-Gomez M. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J Gastroenterol Hepatol. 2014;29:291–295.PubMedCrossRef
28.
Zurück zum Zitat Karmiris K, Avgerinos A, Tavernaraki A, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohn’s Colitis. 2016;10:429–436.CrossRef Karmiris K, Avgerinos A, Tavernaraki A, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohn’s Colitis. 2016;10:429–436.CrossRef
29.
Zurück zum Zitat Cardoneanu A, Cijevschi Prelipcean C, Danciu M, et al. Looking beyond gut inflammation in inflammatory bowel disease. Rom J Morphol Embryol. 2018;59:1097–1105.PubMed Cardoneanu A, Cijevschi Prelipcean C, Danciu M, et al. Looking beyond gut inflammation in inflammatory bowel disease. Rom J Morphol Embryol. 2018;59:1097–1105.PubMed
30.
Zurück zum Zitat Roth N, Biedermann L, Fournier N, et al. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. PLoS One. 2019;14:e0210436.PubMedPubMedCentralCrossRef Roth N, Biedermann L, Fournier N, et al. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. PLoS One. 2019;14:e0210436.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol. 2017;23:6137–6146.PubMedPubMedCentralCrossRef Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol. 2017;23:6137–6146.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Vide J, Osório F, Costa-Silva M, et al. Cutaneous morbidity among inflammatory bowel disease patients: a cohort study. J Crohns Colitis. 2018;12:442–451.PubMedCrossRef Vide J, Osório F, Costa-Silva M, et al. Cutaneous morbidity among inflammatory bowel disease patients: a cohort study. J Crohns Colitis. 2018;12:442–451.PubMedCrossRef
33.
Zurück zum Zitat Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn’s disease. Can J Gastroenterol. 2005;19:603–606.PubMedCrossRef Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn’s disease. Can J Gastroenterol. 2005;19:603–606.PubMedCrossRef
34.
Zurück zum Zitat Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine. 1976;55:401–412.PubMedCrossRef Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine. 1976;55:401–412.PubMedCrossRef
35.
Zurück zum Zitat Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol. 2011;17:2702–2707.PubMedPubMedCentralCrossRef Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol. 2011;17:2702–2707.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol. 1985;80:615–620.PubMed Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol. 1985;80:615–620.PubMed
37.
Zurück zum Zitat McElnea E, Stephenson K, Fulcher T. Pyoderma gangrenosum affecting the eye, orbit, and adnexa. A review. Orbit (Amsterdam, Netherlands).. 2018;37:26–31. McElnea E, Stephenson K, Fulcher T. Pyoderma gangrenosum affecting the eye, orbit, and adnexa. A review. Orbit (Amsterdam, Netherlands).. 2018;37:26–31.
38.
Zurück zum Zitat Gupta AS, Ortega-Loayza AG. Ocular pyoderma gangrenosum: a systematic review. J Am Acad Dermatol. 2017;76:512–518.PubMedCrossRef Gupta AS, Ortega-Loayza AG. Ocular pyoderma gangrenosum: a systematic review. J Am Acad Dermatol. 2017;76:512–518.PubMedCrossRef
39.
Zurück zum Zitat Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–1122.PubMedCrossRef Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–1122.PubMedCrossRef
40.
Zurück zum Zitat Menachem Y, Gotsman I. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Israel Med Assoc J IMAJ. 2004;6:88–90. Menachem Y, Gotsman I. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Israel Med Assoc J IMAJ. 2004;6:88–90.
42.
Zurück zum Zitat Lyon CC, Smith AJ, Griffiths CE, Beck MH. The spectrum of skin disorders in abdominal stoma patients. Br J Dermatol. 2000;143:1248–1260.PubMedCrossRef Lyon CC, Smith AJ, Griffiths CE, Beck MH. The spectrum of skin disorders in abdominal stoma patients. Br J Dermatol. 2000;143:1248–1260.PubMedCrossRef
43.
Zurück zum Zitat Wu XR, Mukewar S, Kiran RP, Remzi FH, Hammel J, Shen B. Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. J Crohn’s Colitis. 2013;7:e171–e177.CrossRef Wu XR, Mukewar S, Kiran RP, Remzi FH, Hammel J, Shen B. Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. J Crohn’s Colitis. 2013;7:e171–e177.CrossRef
44.
Zurück zum Zitat Afifi L, Sanchez IM, Wallace MM, Braswell SF, Ortega-Loayza AG, Shinkai K. Diagnosis and management of peristomal pyoderma gangrenosum: A systematic review. J Am Acad Dermatol. 2018;78:e1191.CrossRef Afifi L, Sanchez IM, Wallace MM, Braswell SF, Ortega-Loayza AG, Shinkai K. Diagnosis and management of peristomal pyoderma gangrenosum: A systematic review. J Am Acad Dermatol. 2018;78:e1191.CrossRef
45.
Zurück zum Zitat Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101:1012–1023.PubMedCrossRef Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101:1012–1023.PubMedCrossRef
46.
Zurück zum Zitat Ott C, Takses A, Obermeier F, Schnoy E, Muller M. Smoking increases the risk of extraintestinal manifestations in Crohn’s disease. World J Gastroenterol. 2014;20:12269–12276.PubMedPubMedCentralCrossRef Ott C, Takses A, Obermeier F, Schnoy E, Muller M. Smoking increases the risk of extraintestinal manifestations in Crohn’s disease. World J Gastroenterol. 2014;20:12269–12276.PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Manguso F, Sanges M, Staiano T, et al. Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. Am J Gastroenterol. 2004;99:327–334.PubMedCrossRef Manguso F, Sanges M, Staiano T, et al. Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. Am J Gastroenterol. 2004;99:327–334.PubMedCrossRef
49.
Zurück zum Zitat Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol. 2018;154:461–466.PubMedCrossRef Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol. 2018;154:461–466.PubMedCrossRef
Metadaten
Titel
Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
verfasst von
Vanessa States
Stephen O’Brien
Jayesh P. Rai
Henry L. Roberts
Mason Paas
Kayla Feagins
Evangeline J. Pierce
Richard N. Baumgartner
Susan Galandiuk
Publikationsdatum
10.01.2020
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 9/2020
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05999-4

Weitere Artikel der Ausgabe 9/2020

Digestive Diseases and Sciences 9/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.